- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06251310
SW-682 dans les tumeurs solides avancées
Une étude de phase 1a/1b sur l'augmentation de la dose et l'augmentation de la dose du SW-682 chez des participants atteints de tumeurs solides avancées enrichies pour ceux présentant des mutations de la voie Hippo
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: US Medical Information
- Numéro de téléphone: 888-275-7376
- E-mail: eMediUSA@emdserono.com
Lieux d'étude
-
-
Arizona
-
Scottsdale, Arizona, États-Unis, 85258
- Recrutement
- HonorHealth Research Institute
-
Chercheur principal:
- Muhammad R Khawaja, MD
-
Contact:
- E-mail: mkhawaja@honorhealth.com
-
-
California
-
Los Angeles, California, États-Unis, 90033
- Recrutement
- USC Norris Comprehensive Cancer Center and Hospital
-
Chercheur principal:
- Diana Hanna, MD
-
Contact:
- E-mail: diana.hanna@med.usc.edu
-
Sacramento, California, États-Unis, 92093
- Recrutement
- UC San Diego Moores Cancer Center
-
Chercheur principal:
- Sandip Patel, MD
-
Contact:
- E-mail: sandippatel@ucsd.edu
-
Santa Monica, California, États-Unis, 90404
- Recrutement
- UCLA Hematology-Oncology - Santa Monica
-
Chercheur principal:
- Arun S Singh, MD
-
Contact:
- E-mail: Asingh@mednet.ucla.edu
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106
- Recrutement
- University Hospital of Cleveland
-
Chercheur principal:
- Afshin Dowlati, MD
-
Contact:
- Numéro de téléphone: 216-844-3951
- E-mail: afshin.dowlati@uhhospitals.org
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Recrutement
- Oregon Health and Science University, Knight Cancer Institute - Marquam Hill
-
Chercheur principal:
- Shivaani Kummar
-
Contact:
- E-mail: kummar@ohsu.edu
-
-
Texas
-
Dallas, Texas, États-Unis, 75230
- Recrutement
- Mary Crowley Research Center US Oncology
-
Chercheur principal:
- Douglas Orr, MD
-
Contact:
- Numéro de téléphone: 972-566-3000
- E-mail: Douglas.Orr@scri.com
-
Houston, Texas, États-Unis, 77030
- Recrutement
- U.T. MD Anderson Cancer Center
-
Chercheur principal:
- Timothy Yap, MD
-
Contact:
- E-mail: TYap@mdanderson.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
-
Histologically confirmed, metastatic, or unresectable solid cancer that has either not responded to or progressed during or after appropriate prior systemic anticancer therapy including chemotherapy, immunotherapy, radiation therapy, or appropriate targeted therapy, or for which there is no treatment available or prior SOC therapy was not tolerated and for which there is no further SOC treatment available
-
Part 1: must have one of the following:
- Mesothelioma with or without NF2 mutations
- Advanced solid tumors with NF2 mutations
- Advanced solid tumors with other Hippo pathway mutations or fusions (e.g., FAT1, LATS1/2, YAP fusions; WWTR1-CAMTA1 in EHE).
-
Part 2: must have the tumor histology and oncogenic mutation or genomic aberration specific to each dose expansion cohort defined below:
- Cohort 1: Participants with mesothelioma with or without NF2 mutations
- Cohort 2: Participants with advanced solid tumors with NF2 mutations
- Cohort 3: Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation
- Cohort 4: SW-682 with appropriate combination therapy.
-
In both parts, participants should have known oncogenic mutation identified by Next Generation Sequencing or local assay
-
Must have archival tumor tissue or agree to a fresh tumor biopsy at screening
-
Measurable disease per RECIST 1.1
-
Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
-
Adequate bone marrow, kidney, hepatic, and coagulation function
Key Exclusion Criteria:
- Evidence of symptomatic CNS metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression
- Clinically significant cardiac disease or abnormal cardiac parameters
- Preexistence or inheritance of a familial renal syndrome
- Concomitant non-anti-arrhythmic medications that are known to prolong the QTc interval
- Concomitant medicines that are known strong/moderate inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) and/or CYP1A2 within 14 days or 5 half-lives before the first dose of study treatment
- Concomitant medicines that are known sensitive substrates of CYP3A4, CYP2C19, CYP2D6, CYP1A2, and/or CYP2B6 within 14 days or 5 half-lives before the first dose of study treatment
- Concomitant medicines that are known sensitive substrates of PGP, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, MATE1, MATE2-K, OCT2
- Clinically significant active infection (bacterial, fungal, or viral)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Phase 1 Dose Escalation Cohorts Ranging in Dose
Participants with advanced solid tumors with or without Hippo pathway mutations will receive SW-682 tablets administered orally in continuous 28-day cycles. SW-682 dosage and frequency of administration will vary by cohort. |
SW-682 tablet administered orally |
|
Expérimental: Part 2 Dose Expansion Cohort 1
Participants with mesothelioma with or without NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
Expérimental: Part 2 Dose Expansion Cohort 2
Participants with advanced solid tumors with NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
Expérimental: Part 2 Dose Expansion Cohort 3
Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
Expérimental: Part 2 Dose Expansion Cohort 4
Participants will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data, with appropriate combination therapy, identified based on Part 1 data. |
SW-682 tablet administered orally Appropriate combination therapy |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Adverse Events (Part 1 Only)
Délai: Up to 24 months
|
Safety and tolerability endpoint evaluation via incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), treatment emergent adverse events (TEAE) |
Up to 24 months
|
|
Maximum Tolerated Dose (Part 1 Only)
Délai: Up to 24 months
|
The maximum tolerated dose (MTD) for SW-682, if any, will be based on safety and tolerability during the first 28 days of treatment in Cycle 1. |
Up to 24 months
|
|
Recommended Dose for Expansion (Part 1 Only)
Délai: Up to 24 months
|
The recommended dose for expansion (RDE) will be determined based on all safety, tolerability, pharmacokinetics (PK), preliminary antitumor efficacy, and other available data from Part 1 of the study. |
Up to 24 months
|
|
Objective Response Rate (Part 2 Only)
Délai: Up to 24 months
|
Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator. |
Up to 24 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in plasma and urine concentrations of SW-682
Délai: Up to 24 months
|
Plasma and urine concentrations of SW-682 and any relevant metabolite(s) will be measured to evaluate systemic exposures and renal elimination. |
Up to 24 months
|
|
Objective Response Rate (Part 1 Only)
Délai: Up to 24 months
|
Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator. |
Up to 24 months
|
|
Disease Control Rate
Délai: Up to 24 months
|
Disease control rate (DCR), defined as the percentage of participants with CR, PR, or stable disease (SD) after starting study treatment. |
Up to 24 months
|
|
Duration of Response
Délai: Up to 24 months
|
Duration of response (DoR), defined as the time from response (CR + PR using RECIST v1.1, mRECIST and/or (GCIG) criteria for CA-125 response in ovarian cancer, as applicable) to disease progression and/or death, whichever occurs first. |
Up to 24 months
|
|
Progression-Free Survival
Délai: Up to 24 months
|
Progression-free survival (PFS), defined as the time from the date of the first administration of study treatment to the first documented disease progression per RECIST v1.1, mRECIST, and/or GCIG CA-125, as applicable, or death due to any cause, whichever occurs first. |
Up to 24 months
|
Collaborateurs et enquêteurs
Les enquêteurs
- Directeur d'études: Medical Responsible, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Maladies pulmonaires
- Tumeurs, glandulaires et épithéliales
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Tumeurs pulmonaires
- Adénome
- Tumeurs mésothéliales
- Tumeurs pleurales
- Mésothéliome
- Mésothéliome malin
- Thérapeutique
- Thérapie de modalité combinée
Autres numéros d'identification d'étude
- TEAD-AST-101
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .